T

Treeline Biosciences

Biotech firm discovering cancer therapies.

Vice President, Head of Quality Assurance

Full-TimePosted on 10/20/2026
$285k - $350k/yr
Expert
Bachelor's, Master's, PharmD, PhD
Watertown, MA, USA
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A Bachelor of Arts or Bachelor of Science degree in Science, Engineering, or a related discipline is required; an advanced degree (Master of Science, PhD, PharmD, or equivalent) is preferred.
  • 15+ years of Quality Assurance experience in an FDA-regulated biotech or pharmaceutical environment, with increasing levels of responsibility, including leadership of a quality function.
  • 5+ years of hands-on experience in one or more technical disciplines before transitioning into Quality Assurance: Chemical Development/Manufacturing, Drug Product Development/Manufacturing, or Analytical Development.
  • Demonstrated success building and leading a quality organization that supports a clinical-stage pharmaceutical company.
  • Mastery of global GxP requirements and applicable international regulations and guidelines.
  • Deep expertise in batch review and disposition for clinical-phase products.
  • Expertise authoring and reviewing SOPs, deviations, investigations, CAPAs, and change controls, and in OOS/OOT management.
  • Expertise performing and managing Quality audits and regulatory inspections.
  • Demonstrated understanding of issue management, risk management, and CAPA effectiveness in manufacturing, laboratory, and clinical environments.
  • Expertise overseeing quality aspects of global vendor networks, including CDMOs, contract laboratories, and distribution partners.
  • Working knowledge of data integrity and computerized system validation requirements.
  • Strong collaboration skills and sufficient technical acumen to partner effectively with CMC, Regulatory, Clinical Operations, Supply Chain, and other key stakeholders.
  • Excellent written and verbal communication skills, with strong executive presence and the ability to influence at all levels of the organization.
  • Ability to manage competing priorities and timelines in a fast-paced, evolving environment.
  • Strong problem-solving skills and ability to implement scalable Quality Systems improvements.
  • Demonstrated commitment to quality, compliance, patient safety, and data integrity.
Responsibilities
  • Serve as the executive owner of quality, setting quality strategy and priorities in line with company objectives and development milestones, and representing Quality across the organization.
  • Build, lead, and develop a quality assurance organization capable of supporting Treeline’s growing global manufacturing, laboratory, and clinical activities and positioned to scale as programs advance.
  • Own and continue to develop Treeline’s Quality Management System in a phase-appropriate, scalable manner, ensuring adherence to applicable global GxP requirements and industry standards, including management review and quality council governance.
  • Define and drive a pragmatic, data-driven Quality strategy, and establish governance frameworks, escalation pathways, and quality metrics that enable proactive risk management and informed decision-making.
  • Provide quality oversight of CDMOs and contract laboratories, including supplier qualification, quality agreements, audit programs, and ongoing performance management.
  • Plan, oversee, and complete audits of manufacturing, laboratory, and distribution partners, and of clinical vendors and sites through a risk-based audit program.
  • Lead external Health Authority inspections, internal audits, and inspection readiness activities, and build toward pre-approval inspection readiness.
  • Review and approve analytical documentation, including methods, validation protocols and reports, specifications, and stability protocols and reports, and manage expiry extensions.
  • Provide Quality input into CMC activities, including process development, tech transfer, manufacturing scale-up, equipment qualification, and process validation and PPQ strategy as programs mature toward registration.
  • Hold accountability for final release or other disposition of clinical trial material, including country-specific release requirements and collaboration with Qualified Persons (QPs).
  • Ensure effective oversight and timely resolution of deviations, investigations, OOS/OOT results, CAPAs, change controls, and product complaints, seeking input from relevant departments so that Quality impact is fully evaluated.
  • Review and approve clinical product labels and the quality aspects of IMPD/IND/NDA CMC sections.
  • Oversee quality aspects of the clinical supply chain and distribution (GDP), including temperature control, storage, shipping, and returns.
  • Oversee pharmacovigilance quality activities to ensure compliance, data integrity, and effective safety surveillance.
  • Ensure appropriate quality oversight of clinical trial execution and GCP compliance, in partnership with Clinical Operations.
  • Drive consistency in quality processes, risk management approaches, computerized system validation, and data integrity standards across the organization.
  • Author, review, and approve SOPs, policies, and controlled quality documentation.
  • Keep current with global health authority laws, regulations, and guidance; identify gaps and implement process improvements resulting from new or revised requirements.
  • Anticipate quality requirements for later-stage development, registration, and approval, and plan systems and resourcing accordingly so the Quality Management System can scale without rework.
  • Manage the Quality budget and resourcing, and participate in project teams and sub-teams as needed.
Desired Qualifications
  • Experience with late-stage development, NDA/MAA submissions, and pre-approval inspections.
  • Working knowledge of oncology drug development.

About the company

Treeline Biosciences develops proprietary therapies for cancer and other serious diseases by conducting in-depth R&D across biology, chemistry, protein sciences, and computational science. Its product work involves discovering and optimizing drug candidates, then licensing these therapies to larger pharmaceutical companies or selling them to healthcare providers, with support from CRO collaborations to speed development. The company differentiates itself through a balanced mix of in-house research and external partnerships, a robust IP strategy, and a team that blends experienced biotech veterans with new talent, all backed by funding from KKR to scale operations. Its goal is to build a sustainable, long-term pipeline of treatments that can reach patients while expanding capabilities and partnerships in the biotech ecosystem.

Company Size

51-200

Company Stage

Series A

Total Funding

$1.1B

Headquarters

Stamford, Connecticut

Founded

2021

Get referred to Treeline Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 8, 2026 merger adds $450 million net cash and $900 million runway.
  • TLN-121 showed complete responses in Phase 1 DLBCL, follicular lymphoma, and TFH PTCL.
  • Treeline expects TLN-121 combination dosing with Roche in Q4 2026.

What critics are saying

  • Standard BioTools merger faces stockholder litigation over fairness and process.
  • TLN-121 remains Phase 1; one safety miss or weak efficacy kills valuation.
  • If the merger closes late or fails, Treeline lacks public-market financing and revenue.

What makes Treeline Biosciences unique

  • Josh Bilenker's team raised $1.2 billion and keeps multiple oncology shots alive.
  • TLN-121, TLN-254, TLN-372, and TLN-499 span lymphoma, KRAS, and platform biology.
  • Roche's September 2, 2026 collaboration validates TLN-121 with Columvi and Lunsumio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend
  • Home Office Stipend
  • Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Clinical Trials Arena
Sep 3rd, 2026
Treeline and Roche collaborate on TLN-121 combo trial for BCL.

Treeline and Roche collaborate on TLN-121 combo trial for BCL. Treeline intends to start combination dosing in these cohorts in the fourth quarter of 2026. Treeline Biosciences has signed a clinical trial collaboration and supply agreement with Roche for a Phase I study assessing the combination of Treeline's BCL6 degrader, TLN-121, with Roche's CD20xCD3 T-cell-engaging bispecific antibodies, glofitamab (Columvi) and mosunetuzumab (Lunsumio), in patients with B-cell lymphomas (BCL). The trial will assess the combinations in separate cohorts, including individuals with diffuse large B-cell lymphoma (DLBCL). Under the collaboration, Treeline Biosciences will sponsor and oversee the Phase I dose-escalation and expansion study, with Roche supplying glofitamab and mosunetuzumab for particular expansion cohorts. Treeline intends to start combination dosing in these cohorts in the fourth quarter of 2026. Treeline co-founder and CEO Josh Bilenker said: "CD20xCD3 T-cell-engaging bispecific antibodies such as glofitamab and mosunetuzumab have already transformed the treatment of B-cell lymphomas. Clinical Trials Arena is excited to build on that progress in collaboration with Roche. "We have generated exciting preclinical data suggesting that TLN-121 enhances the anti-tumour activity of both CD20xCD3 T-cell-engaging bispecific antibodies and CD19 CAR-T cell therapy. These results were predicted by published studies that showed BCL6 impairs the formation of an effective immune synapse between T-cells and B-cells." TLN-121 has shown single-agent activity, including complete responses, in an ongoing Phase I trial in late-line DLBCL, follicular lymphoma and T follicular helper peripheral T-cell lymphoma. Treeline is a clinical-stage biopharmaceutical company with a pipeline in oncology, neurology and immunology. Last month, Evexta Bio and Roche entered a clinical trial collaboration and supply agreement for a Phase Ib study investigating the combination of rupitasertib and giredestrant in patients with advanced or metastatic breast cancer. This marks the first clinical collaboration for Evexta Bio involving its investigational compound rupitasertib and for Roche with giredestrant, its selective estrogen receptor degrader (SERD). Give your business an edge with its leading industry insights.

cash.ch
Sep 2nd, 2026
Roche cooperates with Treeline on lymphoma therapy.

Roche cooperates with Treeline on lymphoma therapy. Roche is collaborating with the US biotech company Treeline Biosciences on the development of a new combination therapy for certain forms of lymphoma. 02.09.2026 04:50 In the collaboration, Treeline's drug candidate TLN-121 in combination with Roche's drugs Columvi (glofitamab) and Lunsumio (mosunetuzumab) will be investigated. The combinations are to be studied in patients with B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), as Treeline announced on Wednesday. Treeline will finance and conduct the phase 1 study, while Roche will provide the already approved cancer drugs glofitamab and mosunetuzumab for certain study groups. Financial details were not disclosed. Treeline plans to begin the combined treatment in the fourth quarter of 2026. Preclinical investigations have provided evidence that TLN-121 could enhance the effect of the two Roche therapies. TLN-121 is currently already being tested as a monotherapy in a phase 1 study.

Contract Pharma
Sep 2nd, 2026
Treeline, Roche partner on TLN-121 lymphoma trial.

Treeline, Roche partner on TLN-121 lymphoma trial. Phase 1 study will evaluate TLN-121 with Roche's glofitamab and mosunetuzumab in patients with B-cell lymphomas. September 2, 2026 Associate Editor, Contract Pharma Treeline Biosciences Inc. has entered into a clinical trial collaboration and supply agreement with Roche to study TLN-121, Treeline's BCL6 degrader, alongside Roche's CD20xCD3 T-cell-engaging bispecific antibodies glofitamab and mosunetuzumab in patients with B-cell lymphomas. The Phase 1 study will evaluate the combinations in separate cohorts, including patients with diffuse large B-cell lymphoma (DLBCL), a common and aggressive form of B-cell lymphoma. Treeline will sponsor and conduct the Phase 1 dose-escalation and expansion study, while Roche will provide glofitamab and mosunetuzumab for specified expansion cohorts. Treeline expects to begin combination dosing in those cohorts in the fourth quarter of 2026. "CD20xCD3 T-cell-engaging bispecific antibodies such as glofitamab and mosunetuzumab have already transformed the treatment of B-cell lymphomas. We are excited to build on that progress in collaboration with Roche," said Josh Bilenker, M.D., co-founder and CEO of Treeline. TLN-121 is already being evaluated as a single agent in an ongoing Phase 1 clinical trial, where Treeline said it has shown activity, including complete responses in late-line DLBCL, follicular lymphoma (FL), and T follicular helper peripheral T-cell lymphoma (TFH PTCL). The collaboration is intended to test whether degrading BCL6 can make lymphoma cells more responsive to T-cell-engaging therapies, a strategy supported by Treeline's preclinical findings. "We have generated exciting preclinical data suggesting that TLN-121 enhances the anti-tumor activity of both CD20xCD3 T-cell-engaging bispecific antibodies and CD19 CAR-T cell therapy. These results were predicted by published studies that showed BCL6 impairs the formation of an effective immune synapse between T- and B-cells," Bilenker added.

My Malone Telegram
Jun 19th, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: notifying investors of the following investigations: AstroNova, Inc. (Nasdaq - ALOT), Open Lending Corporation (Nasdaq - LPRO), Huntsman Corporation (NYSE - HUN)...

BRODSKY & SMITH SHAREHOLDER UPDATE: notifying investors of the following investigations: AstroNova, Inc. (Nasdaq - ALOT), Open Lending Corporation (Nasdaq - LPRO), Huntsman Corporation (NYSE - HUN), Standard BioTools Inc. (Nasdaq - LAB). * Jun 19, 2026 BALA CYNWYD, Pa., June 19, 2026 (GLOBE NEWSWIRE) - Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you. AstroNova, Inc. (Nasdaq - ALOT) Under the terms of the Merger Agreement, AstroNova will be acquired by Arcline Investment Management for $29.00 per share in cash in an all-cash transaction with a total enterprise value of approximately $272 million. The investigation concerns whether the AstroNova Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Open Lending Corporation (Nasdaq - LPRO) Under the terms of the Merger Agreement, Open Lending will be acquired by ANV Group Holdings Ltd. for $3.15 per share. The investigation concerns whether the Open Lending Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Huntsman Corporation (NYSE - HUN) Under the terms of the Merger Agreement, Huntsman will be acquired by Olin Corporation (NYSE - OLN) whereby Huntsman shareholders will receive 0.5476 shares in Olin for every one (1) share of Huntsman. Upon completion of the transaction, Olin shareholders will own approximately 54.5% and Huntsman shareholders will own approximately 45.5% of the combined company. The investigation concerns whether the Huntsman Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Standard BioTools Inc. (Nasdaq - LAB) Under the terms of the Merger Agreement, Standard BioTools will be acquired by Treeline Biosciences, Inc. At the closing of the proposed combination, pre-merger Standard BioTools stockholders are expected to own approximately 16% of the combined company, and pre-merger Treeline stockholders are expected to own approximately 84% of the combined company. The investigation concerns whether the Standard BioTools Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Endpoints News
Jun 8th, 2026
Treeline to go public via reverse merger with Standard BioTools.

Treeline to go public via reverse merger with Standard BioTools. News reporter. Treeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.